Research Of The Relationship Between The Prognosis And Expression Of P16 Protein, Nm23 Protein And VEGF In Transfered NSCLC

Objective To study the expression of p16 protein, nm23 protein and vascular endothelial growth factor(VEGF)in NSCLC (non-small cell lung cancer) tissue, explore the correlation of p16 protein, nm23 protein, VEGF with the clinical pathology and prognosis of NSCLC. These will supply the impersonal evidence for early diagnose, early therapy, prognosis estimation of NSCLC.Methods The expression of p16 protein, nm23 protein and VEGF in 80 cases of patients with NSCLC and 20 cases of patients with lung benign disease (Control group) was detected by S-P immunohistochemical technique, its correlation to clinical pathologic characteristic of NSCLC was explored ,including age, sex, histological type, invasion degree and lymph node metastasis. Summarizing the character of expression of p16 protein, nm23 protein and VEGF in NSCLC and the correlation of these three targets.Results (1) The expressionrates of p16 protein, nm23 protein and VEGF were 50.00%, 55.00% 76.25% in 80 patients with NSCLC. While the expression rates of p16 protein, nm23 protein and VEGF were 95.00%, 90.00%, 20.00% in 20 patients with lung benign disease. The expression rates of the p16 protein and nm23 protein in the NSCLC patients were lower than those of the patients with lung benign disease, there have significant statistical difference (p＜0.05), while VEGF were contrary, there also have significant statistical difference (p＜0.05). (2) The expression rates of p16 protein, nm23 protein and VEGF in the group under 60 were 52.38%, 54.76%, 76.19%, while those in the group beyond 60 were 47.37%, 55.26%, 76.32%. There was no significant statistical difference between two groups (p＞0.05). On the other hand, the expression rates of p16 protein, nm23 protein and VEGF were 47.92%, 54.17%, 77.08% in male patients with NSCLC. While the expression rates of p16 protein, nm23 protein and VEGF were 53.13%, 56.25%, 75.00% in female patients with NSCLC. There was also no significant statistical difference between two groups (p＞0.05). (3) The expression rates of p16 protein, nm23 protein and VEGF in the group of scalelikecarcinoma were 52.08%, 58.33%, 72.92%, while those in the group of adenocarcinoma were 46.88%, 50.00%, 81.25%. There was no significant statistical difference between two groups (p＞0.05). (4) The expression rate of p16 protein, nm23 protein and VEGF in peripheral carcinoma group were 50.00%, 52.17%, 76.09%, Those in centric carcinoma group were 50.00%, 58.82%, 76.47%, There was no significant differentiation between the expressionrates of p16 protein, nm23 protein and VEGF in two groups (p＞0.05). (5) The expression rates of p16 protein, nm23 protein and VEGF in experimental group whose diameter≤3 cm were 71.43%, 71.43%, 60.71%, while those in experimental group whose diameter＞3 cm were 38.46%, 46.15%, 84.62%, The expression rates of p16 protein, nm23 protein in experimental group whose diameter≤3 cm were higher than the group whose diameter＞3 cm, however the expression rates of VEGF in experimental group whose diameter≤3 cm were lower than the group whose diameter＞3 cm. There all have significant statistical difference (p＜0.05). (6) The expression rates of p16 protein, nm23 protein and VEGF in well-moderated differentiation carcinoma group were 60.38%, 64.15%, 66.04%. Those in poor differentiation carcinoma group were 29.63%, 37.04%, 96.30%.The expression rates of p16 protein, nm23 protein in well-moderated differentiation carcinoma group were significantly higher than those in poor differentiation carcinoma group, however The expression rates of VEGF in well-moderated differentiation carcinoma group were significantly lower than those in poor differentiation carcinoma group, there have significant statistical difference (p＜0.05).(7) The expression rates of p16 protein, nm23 protein and VEGF in groupⅠ-Ⅱwere 62.50%, 67.86%, 69.64%; Those in groupⅢ-Ⅳwere 20.83%, 25.00%, 91.67%。The expression rates of p16 protein, nm23 protein in groupⅠ-Ⅱwere significantly higher than those in groupⅢ-Ⅳ, however the expression rates of VEGF in groupⅠ-Ⅱwere significantly lower than those in groupⅢ-Ⅳ, there all have significant statistical difference (p＜0.05). (8) The expression rates of p16 protein, nm23 protein and VEGF in group with lymph node metastasis were 43.10%, 46.55%, 86.21%, while those in group without lymph node metastasis were 68.18%, 77.27%, 50.00%, The expression rates of p16 protein and nm23 protein of the group with lymph metastasis were significantly lower than those of the group without lymph node metastasis (p＜0.05), however the expression rate of VEGF of the group with lymph metastasis was higher than that of the group without lymph node metastasis, there all have significant statistical difference (p＜0.05). (9) The expression rates of p16 protein, nm23 protein and VEGF in group of NSCLC with metastasis were 34.09%, 40.91%, 84.09%; while those in group of NSCLC without metastasis were 68.18%, 77.27%, 50.00%, The expression rates of p16 protein and nm23 protein in group of NSCLC with metastasis were significantly lower than those in group of NSCLC without metastasis, however the expression rate of VEGF in group of NSCLC with metastasis was higher than that in group of NSCLC without metastasis, there all have significant statistical difference (p＜0.05). (10) There was some correlation between the expression of p16 protein, nm23 protein, VEGF and the prognosis. More the expression of exceptional protein, worse the prognosis of NSCLC.Conclusions p16 protein, nm23 protein and VEGF play important roles in the occur, grow and prognosis of NSCLC. The expression of them is associated with histological differentiation, lymph node metastasis, tumor stage of TNM and tumor size, but not associated with age, sex, type and position. There have some correlation between the expressionof p16 protein, nm23 protein, VEGF and the prognosis. More the expressionof exceptional protein, Worse the prognosis of NSCLC. Detecting the expression of p16 protein, nm23 protein and VEGF may be useful for the early diagnose, the early therapy and the estimation of prognosis in NSCLC.